EUVIMEDEUVIMED entdecken
Open Access

Enhanced Killing of Methicillin-Resistant Staphylococcus aureus With Ceftaroline or Vancomycin in Combination With Carbapenems

Allen Jankeel, Gabriel Pérez-Parra iD, Anuj K Khetarpal, Ivan A Alvarado iD, Victor Nizet iD, George Sakoulas iD, Erlinda R Ulloa iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Allen Jankeel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, Irvine School of Medicine. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Cephalosporins, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, /.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high rates of treatment failure, even when antibiotics showing in vitro susceptibility are used. Early optimization of therapy is crucial to reduce morbidity and mortality. Building on our previous research on carbapenem therapy for methicillin-susceptible S aureus bacteremia, we examined the utility of adjunctive carbapenems (ertapenem or meropenem) to enhance the efficacy of ceftaroline or vancomycin for treatment of MRSA.

Methods

The effectiveness of combination therapy versus monotherapy against MRSA was assessed using checkerboard, time-kill, and human whole blood killing assays, as well as a murine bacteremia model. Additionally, we performed transcriptomic analysis and conducted human platelet and antimicrobial peptide killing assays on MRSA pretreated with subtherapeutic concentrations of ceftaroline and carbapenems. The supernatants from these MRSA isolates were used to treat platelets, and cytotoxicity was assessed via lactate dehydrogenase release assays.

Results

Although not used for MRSA, we identified striking in vitro and in vivo synergy between carbapenems and ceftaroline or vancomycin. MRSA pretreated with subtherapeutic ceftaroline-carbapenem therapy revealed transcriptional shifts indicative of reduced antibiotic resistance, virulence, and host immune evasion. Supernatants from these MRSA isolates also caused less platelet injury compared to monotherapy. Furthermore, MRSA pretreated with ceftaroline and carbapenems demonstrated increased susceptibility to killing by human platelets and the antimicrobial peptide LL-37.

Conclusions

The therapeutic success of adjunctive carbapenems appears driven by multiple mechanisms, including direct drug–drug synergy with first-line anti-MRSA agents, attenuation of resistance and virulence factors, and enhancement of immune-mediated killing, each warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusCephalosporinsAnti-Bacterial AgentsCarbapenemsVancomycinStaphylococcal InfectionsCeftarolineHumansAnimalsMiceMicrobial Sensitivity TestsBacteremiaDrug Therapy, CombinationDrug Synergism

Stichwörter der Autor:innen

MRSAbacteremiacarbapenemsceftarolinecombination therapyendocarditisertapenemmeropenemvancomycin

Substanzen

CeftarolineCephalosporinsAnti-Bacterial AgentsCarbapenemsVancomycin

Autor:innen und Institutionen

  • Department of Pediatrics, University of California, Irvine School of Medicine.
  • Department of Pediatrics, Division of Host-Microbe Systems and Therapeutics.
  • Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, University of California, San Diego School of Medicine, La Jolla.
  • Division of Infectious Diseases, Sharp Rees-Stealy Medical Group, San Diego, California.
  • Division of Infectious Disease, Children's Hospital of Orange County, Orange, California.

ORCID-Profile: Gabriel Pérez-Parra, Ivan A Alvarado, Victor Nizet, George Sakoulas, Erlinda R Ulloa

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • /

Zitieren

APA

Jankeel, A., Pérez-Parra, G., Khetarpal, A. K., Alvarado, I. A., Nizet, V., Sakoulas, G., & Ulloa, E. R. (2025). Enhanced Killing of Methicillin-Resistant Staphylococcus aureus With Ceftaroline or Vancomycin in Combination With Carbapenems. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf010

Vancouver

Jankeel A, Pérez-Parra G, Khetarpal AK, Alvarado IA, Nizet V, Sakoulas G, et al. Enhanced Killing of Methicillin-Resistant Staphylococcus aureus With Ceftaroline or Vancomycin in Combination With Carbapenems. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf010

BibTeX
@article{Jankeel2025,
  author = {Jankeel, Allen and Pérez-Parra, Gabriel and Khetarpal, Anuj K and Alvarado, Ivan A and Nizet, Victor and Sakoulas, George and Ulloa, Erlinda R},
  title = {Enhanced Killing of Methicillin-Resistant Staphylococcus aureus With Ceftaroline or Vancomycin in Combination With Carbapenems},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf010}
}
Kostenlos starten →